Investigating how Sema3C signaling affects Wnt signaling in glioblastoma
Sema3C Signaling as an Alternative Activator of Canonical Wnt Signaling in Glioblastoma
This study is looking at how a protein called Sema3C affects brain cancer cells and their growth, with the hope of finding better treatments that work alongside current therapies to help patients with glioblastoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11072044 on NIH RePORTER |
What this research studies
This research explores the role of Sema3C signaling in glioblastoma, particularly how it activates the Wnt signaling pathway, which is often disrupted in various cancers. The study aims to understand the mechanisms behind this activation and how it contributes to the growth and survival of glioma stem-like cells. By using mouse models, the researchers will assess the potential of targeting Sema3C signaling to enhance the effectiveness of existing Wnt inhibitors, which have shown limited success in clinical trials. This could lead to the development of new therapeutic strategies with reduced toxicity for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who may benefit from novel therapeutic approaches targeting the Wnt signaling pathway.
Not a fit: Patients with other types of cancer or those not diagnosed with glioblastoma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for glioblastoma patients.
How similar studies have performed: While the approach of targeting Wnt signaling is being explored, the specific role of Sema3C in this context is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Yu, Jennifer S — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Yu, Jennifer S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.